CD28 Screening Services
Cluster of Differentiation 28, or CD28, is a protein which is necessary for the activation and survival of T cells. The CD28 receptor can bind to B7-1 and B7-2, proteins expressed mostly by antigen presenting cells (APCs). The interaction between B7 proteins and CD28 receptors serves as a potential method to enhance anti-tumor immunity by developing therapies that mimic B7 proteins and activate the CD28 receptor. Alternatively, in autoimmune diseases such as ...
Immunotherapy Biochemical Screening Services
Immunotherapy is a type of medical treatment that engages the body's immune system to fight diseases, such as cancer, infections, and autoimmune disorders. It works by either stimulating the immune system to attack cancer cells or other disease-causing agents, or by using synthetic proteins or antibodies to target specific molecules on the surface of cancer cells or other pathogens. Immunotherapy has shown prom...
Combining Therapies for Targeting Immune Checkpoints
| IMMUNE CHECKPOINTS | | KINASES | | PARPS | | HDACS | | CAR T-CELL THERAPY |
Cancer is a balance between the defens...
CAR T-Cell Therapy
Overview
CAR-T is a cross of immunotherapy, gene therapy, and cellular therapy. Many successful immunotherapies are based on checkpoint inhibitors that block the mechanisms tumor cells use to hide from T cells. CAR-T immunotherapies go one step further by engineering T cells to enhance the immune response against a specific tumor antigen. CAR-T is a promising approach for cancer and other diseases, especially severe cancers that do not respond well to othe...
Ubiquitination and CBL
Introduction
Ubiquitination is a process that involves the covalent binding of a 76 amino acid protein called ubiquitin to a target protein. This process is crucial for cellular homeostasis, regulating many cellular processes such as protein degradation, DNA repair, and cell signaling. Ubiquitination is a multistep process mediated by a group of enzymes known as ubiquitin ligases. Gain or loss of function of any of these enzymes can lead to impaired cellular functio...
TIGIT, CD155, & CD226
Promising Targets for Cancer Immunotherapies
It’s possible someone you know has benefited from cancer treatments based on checkpoint receptors. Therapeutic antibodies targeting PD-1 and CTLA-4 pathways have already added years to the lives of lucky patients. Unfortunately, not everyone responds to these treatments. This resistance drives the search for new therapies to extend the successes of existing PD-1 and CTLA-4-based treatme...
The Promise of NK Cell Therapeutics
Introduction
NK cells are the first line of defense against cancer and have been in the spotlight as a cancer therapy in the last decade. Their advantages versus T cells, such as their safety profile and not requiring MHC (Major Histocompatibility Complex)-antigen stimulation to become cytotoxic, have made NK cells attractive. However, as with T cells, the TME (tumor microenvironment) can suppress their activity, and infiltration into solid tumors is s...
Citations
This page contains a list of scientific journal articles that have cited BPS products and services since 2013. We would like to congratulate all our loyal customers on their contributions to the scientific community. Our customers are truly amazing and dedicated scientists and this is evidenced by the outstanding research they are doing.
Search By Product Name or Catalog Number
Name
Title
10X HAT Assay Buffer (50095...
